白蛋白尿变化与糖尿病主要临床结局风险:ADVANCE-ON研究结果
在ADVANCE-ON研究中分析8,766例2型糖尿病参与者,按2年间尿白蛋白/肌酐比值(UACR)变化分组。中位随访7.7年,UACR升高≥30%独立预测主要结局风险增加(HR 1.26;95%CI 1.13-1.41),UACR降低与风险降低无显著关联(HR 0.93;95%CI 0.83-1.04),校正均值回归后真实降低的效应显著(HR 0.84;95%CI 0.75-0.94)。
要点
- UACR 2年升高≥30%独立预测主要结局风险增加(HR 1.26;95%CI 1.13-1.41)。
- UACR降低与主要结局风险降低无显著关联(HR 0.93;95%CI 0.83-1.04)。
- 校正均值回归后,真实UACR降低对主要结局的效应显著(HR 0.84;95%CI 0.75-0.94)。
核心结论
- UACR变化可预测2型糖尿病主要临床结局和死亡风险的变化,支持随时间监测白蛋白尿变化的预后价值。
研究设计与样本
- 分析ADVANCE-ON研究中8,766例参与者的数据,计算间隔2年的UACR变化并分为UACR降低≥30%、轻微变化、UACR升高≥30%三组;按基线UACR三分位分组重复分析以校正均值回归(RtM)。
- 采用Cox回归模型估计风险比(HR)。
主要发现
- 中位随访7.7年期间观察到2,191例主要结局。
- UACR 2年升高≥30%较轻微变化独立预测主要结局风险增加(HR 1.26;95% CI 1.13-1.41)。
- UACR降低与主要结局风险降低无显著关联(HR 0.93;95% CI 0.83-1.04)。
- 校正均值回归后,真实UACR降低对主要结局的效应显著(HR 0.84;95% CI 0.75-0.94),而UACR升高的估计效应不变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS: Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease in UACR was not significantly associated with lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75-0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS: Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.
引用
- Jun M, Ohkuma T, Zoungas S, et al. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care. 2017. PMID: 29079715. doi:10.2337/dc17-1467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。